中国卒中杂志 ›› 2023, Vol. 18 ›› Issue (01): 17-41.DOI: 10.3969/j.issn.1673-5765.2023.01.002
王伊龙, 陈玮琪, 叶瑾怡, 周梦圆, 江凌玲, 刘东, 邱宝山, 高颖, 赵一龙, 王赞, 李鹏飞
收稿日期:
2023-01-10
出版日期:
2023-01-20
发布日期:
2023-01-20
通讯作者:
王伊龙 yilong528@gmail.com
Received:
2023-01-10
Online:
2023-01-20
Published:
2023-01-20
王伊龙, 陈玮琪, 叶瑾怡, 周梦圆, 江凌玲, 刘东, 邱宝山, 高颖, 赵一龙, 王赞, 李鹏飞. 脑小血管病:回眸2022[J]. 中国卒中杂志, 2023, 18(01): 17-41.
WANG Yilong, CHEN Weiqi, YE Jinyi, ZHOU Mengyuan, JIANG Lingling, LIU Dong, QIU Baoshan, GAO Ying, ZHAO Yilong, WANG Zan, LI Pengfei . Highlights in Cerebral Small Vessel Disease in 2022[J]. Chinese Journal of Stroke, 2023, 18(01): 17-41.
[1] CHARIDIMOU A,PANTONI L,LOVE S. The concept of sporadic cerebral small vessel disease:a road map on key definitions and current concepts[J]. Int J Stroke,2016,11(1):6-18. [2] SMITH E E,MARKUS H S. New treatment approaches to modify the course of cerebral small vessel diseases[J]. Stroke,2020,51(1):38-46. [3] MARKUS H S,FLIER W M,SMITH E E,et al. Framework for clinical trials in cerebral small vessel disease(FINESSE):a review[J]. JAMA Neurol,2022,79(11):1187-1198. [4] CANNISTRARO R J,BADI M,EIDELMAN B H,et al. CNS small vessel disease:a clinical review[J]. Neurology,2019,92(24):1146-1156. [5] BERNBAUM M,MENON B K,FICK G,et al. Reduced blood flow in normal white matter predicts development of leukoaraiosis[J]. J Cereb Blood Flow Metab,2015,35(10):1610-1615. [6] VEEN P H,MULLER M,VINCKEN K L,et al. Longitudinal relationship between cerebral small-vessel disease and cerebral blood flow:the second manifestations of arterial disease-magnetic resonance study[J]. Stroke,2015,46(5):1233-1238. [7] TEICH A F,SAKURAI M,PATEL M,et al. PDE5 exists in human neurons and is a viable therapeutic target for neurologic disease[J]. J Alzheimers Dis,2016,52(1):295-302. [8] VASITA E,YASMEEN S,ANDOH J,et al. The cGMP-degrading enzyme phosphodiesterase-5(PDE5)in cerebral small arteries of older people[J]. J Neuropathol Exp Neurol,2019,78(2):191-194. [9] FORGUE S T,PATTERSON B E,BEDDING A W,et al. Tadalafil pharmacokinetics in healthy subjects[J]. Br J Clin Pharmacol,2006,61(3):280-288. [10] GARCIA-OSTA A,CUADRADO-TEJEDOR M,GARCIA-BARROSO C,et al. Phosphodiesterases as therapeutic targets for Alzheimer’s disease[J]. ACS Chem Neurosci,2012,3(11):832-844. [11] PAULS M M H,BINNIE L R,BENJAMIN P,et al. The PASTIS trial:testing tadalafil for possible use in vascular cognitive impairment[J]. Alzheimers Dement,2022,18(12):2393-2402. [12] PFLANZ C P,EGLE M S,O’BRIEN J T,et al. Association of blood pressure lowering intensity with white matter network integrity in patients with cerebral small vessel disease[J/OL]. Neurology,2022,99(17):e1945-e1953[2023-01-03]. https://doi.org/10.1212/wnl.0000000000201018. [13] UMEMOTO S,OGIHARA T,MATSUZAKI M,et al. Effects of calcium channel blocker-based combinations on intra-individual blood pressure variability:post hoc analysis of the COPE trial[J]. Hypertens Res,2016,39(1):46-53. [14] GOLDSTEIN E D,WOLCOTT Z,GARG G,et al. Effect of antihypertensives by class on cerebral small vessel disease:a post hoc analysis of SPRINT-MIND[J]. Stroke,2022,53(8):2435-2440. [15] SHIN H K,SALOMONE S,AYATA C. Targeting cerebrovascular Rho-kinase in stroke[J]. Expert Opin Ther Targets,2008,12(12):1547-1564. [16] MATSUI T,AMANO M,YAMAMOTO T,et al. Rho-associated kinase,a novel serine/threonine kinase,as a putative target for small GTP binding protein Rho[J]. Embo J,1996,15(9):2208-2216. [17] AYKAN S A,XIE H Y,ZHENG Y,et al. Rho-kinase inhibition improves the outcome of focal subcortical white matter lesions[J]. Stroke,2022,53(7):2369-2376. [18] BENAVENTE O R,HART R G,MCCLURE L A,et al. Effects of clopidogrel added to aspirin in patients with recent lacunar stroke[J]. N Engl J Med,2012,367(9):817-825. [19] KWOK C S,SHOAMANESH A,COPLEY H C,et al. Efficacy of antiplatelet therapy in secondary prevention following lacunar stroke:pooled analysis of randomized trials[J]. Stroke,2015,46(4):1014-1023. [20] SHINOHARA Y,KATAYAMA Y,UCHIYAMA S,et al. Cilostazol for prevention of secondary stroke(CSPS 2):an aspirin-controlled,double-blind,randomised non-inferiority trial[J]. Lancet Neurol,2010,9(10):959-968. [21] OYAMA N,YAGITA Y,KAWAMURA M,et al. Cilostazol,not aspirin,reduces ischemic brain injury via endothelial protection in spontaneously hypertensive rats[J]. Stroke,2011,42(9):2571-2577. [22] KIM B C,YOUN Y C,JEONG J H,et al. Cilostazol versus aspirin on white matter changes in cerebral small vessel disease:a randomized controlled trial[J]. Stroke,2022,53(3):698-709. [23] BLAIR G W,JANSSEN E,STRINGER M S,et al. Effects of cilostazol and isosorbide mononitrate on cerebral hemodynamics in the LACI-1 randomized controlled trial[J]. Stroke,2022,53(1):29-33. [24] GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories,1990-2019:a systematic analysis for the global burden of disease study 2019[J]. Lancet,2020,396(10258):1204-1222. [25] WASSENAAR T M,YAFFE K,VAN DER WERF Y D,et al. Associations between modifiable risk factors and white matter of the aging brain:insights from diffusion tensor imaging studies[J/OL]. Neurobiol Aging,2019,80:56-70[2023-01-03]. https://doi.org/10.1016/j.neurobiolaging.2019.04.006. [26] BERRY C,SIDIK N,PEREIRA A C,et al. Small-vessel disease in the heart and brain:current knowledge,unmet therapeutic need,and future directions[J/OL]. J Am Heart Assoc,2019,8(3):e011104[2023-01-03]. https://doi.org/10.1161/jaha.118.011104. [27] MEJIA-RENTERIA H,TRAVIESO A,MATÍAS-GUIU J A,et al. Coronary microvascular dysfunction is associated with impaired cognitive function:the cerebral-coronary connection study(C3 study)[J]. Eur Heart J,2023,44(2):113-125. [28] FERGUSON A C,THRIPPLETON S,HENSHALL D,et al. Frequency and phenotype associations of rare variants in 5 monogenic cerebral small vessel disease genes in 200,000 UK biobank participants[J/OL]. Neurol Genet,2022,8(5):e200015[2023-01-03]. https://doi.org/10.1212/nxg.0000000000200015. [29] MISHRA A,DUPLAÀ C,VOJINOVIC D,et al. Gene-mapping study of extremes of cerebral small vessel disease reveals TRIM47 as a strong candidate[J]. Brain,2022,145(6):1992-2007. [30] HARSHFIELD E L,SANDS C J,TULADHAR A M,et al. Metabolomic profiling in small vessel disease identifies multiple associations with disease severity[J]. Brain,2022,145(7):2461-2471. [31] PEROSA V,OLTMER J,MUNTING L P,et al. Perivascular space dilation is associated with vascular amyloid-β accumulation in the overlying cortex[J]. Acta Neuropathol,2022,143(3):331-348. [32] VELUW S J,BIESSELS G J,BOUVY W H,et al. Cerebral amyloid angiopathy severity is linked to dilation of juxtacortical perivascular spaces[J]. J Cereb Blood Flow Metab,2016,36(3):576-580. [33] MONTAGNE A,ZHAO Z,ZLOKOVIC B V. Alzheimer’s disease:a matter of blood-brain barrier dysfunction? [J]. J Exp Med,2017,214(11):3151-3169. [34] CUADRADO-GODIA E,DWIVEDI P,SHARMA S,et al. Cerebral small vessel disease:a review focusing on pathophysiology,biomarkers,and machine learning strategies[J]. J Stroke,2018,20(3):302-320. [35] KALARIA R N. Small vessel disease and Alzheimer’s dementia:pathological considerations[J/OL]. Cerebrovasc Dis,2002,13(Suppl 2):48-52[2023-01-03]. https://doi.org/10.1159/000049150. [36] CHENG X,HE P,YAO H L,et al. Occludin deficiency with BACE1 elevation in cerebral amyloid angiopathy[J]. Neurology,2014,82(19):1707-1715. [37] ROSSNER S,LANGE-DOHNA C,ZEITSCHEL U,et al. Alzheimer’s disease beta-secretase BACE1 is not a neuron-specific enzyme[J]. J Neurochem,2005,92(2):226-234. [38] BOURASSA P,TREMBLAY C,SCHNEIDER J A,et al. Beta-amyloid pathology in human brain microvessel extracts from the parietal cortex:relation with cerebral amyloid angiopathy and Alzheimer’s disease[J]. Acta Neuropathol,2019,137(5):801-823. [39] ZHOU H Y,GAO F,YANG X L,et al. Endothelial BACE1 impairs cerebral small vessels via tight junctions and eNOS[J]. Circ Res,2022,130(9):1321-1341. [40] CAI M F,JACOB M A,VAN LOENEN M R,et al. Determinants and temporal dynamics of cerebral small vessel disease:14-year follow-up[J]. Stroke,2022,53(9):2789-2798. [41] VERBURGT E,JANSSEN E,JACOB M A,et al. Role of small acute hyperintense lesions in long-term progression of cerebral small vessel disease and clinical outcome:a 14-year follow-up study[J]. J Neurol Neurosurg Psychiatry,2023,94(2):144. [42] KUO C Y,TAI T M,LEE P L,et al. Improving individual brain age prediction using an ensemble deep learning framework[J/OL]. Frontiers in psychiatry,2021,12:626677[2023-01-03]. https://doi.org/10.3389/fpsyt.2021.626677. [43] WARDLAW J M,SMITH C,DICHGANS M. Small vessel disease:mechanisms and clinical implications[J]. Lancet Neurol,2019,18(7):684-696. [44] LEE P L,KUO C Y,WANG P N,et al. Regional rather than global brain age mediates cognitive function in cerebral small vessel disease[J/OL]. Brain Commun,2022,4(5):fcac233[2023-01-03]. https://doi.org/10.1093/braincomms/fcac233. [45] HABES M,POMPONIO R,SHOU H C,et al. The brain chart of aging:machine-learning analytics reveals links between brain aging,white matter disease,amyloid burden,and cognition in the iSTAGING consortium of 10,216 harmonized MR scane[J]. Alzheimers Dement,2021,17(1):89-102. [46] KATZMAN R,TERRY R,DETERESA R,et al. Clinical,pathological,and neurochemical changes in dementia:a subgroup with preserved mental status and numerous neocortical plaques[J]. Ann Neurol,1988,23(2):138-144. [47] SNOWDON D A,KEMPER S J,MORTIMER J A,et al. Linguistic ability in early life and cognitive function and Alzheimer’s disease in late life. Findings from the Nun study[J]. JAMA,1996,275(7):528-532. [48] DEJONG N R,JANSEN J F A,VAN BOXTEL M P J,et al. Cognitive resilience depends on white matter connectivity:the Maastricht study[J/OL]. Alzheimers Dement,2022:12758[2023-01-03]. https://doi.org/10.1002/alz.12758. [49] NG F C,CHURILOV L,YASSI N,et al. Prevalence and significance of impaired microvascular tissue reperfusion despite macrovascular angiographic reperfusion(No-Reflow)[J/OL]. Neurology,2022,98(8):e790-e801[2023-01-03]. https://doi.org/10.1212/wnl.0000000000013210. [50] QIU B S,ZHAO Z C,WANG N,et al. A systematic observation of vasodynamics from different segments along the cerebral vasculature in the penumbra zone of awake mice following cerebral ischemia and recanalization[J/OL]. J Cereb Blood Flow Metab,2022:271678x221146128. https://doi.org/10.1177/0271678x221146128. |
[1] | 李月容, 秦秀德, 党朝晖, 陆韵薇, 蔡甜甜, 蔡浩斌, 卜凡. 小胶质细胞对卒中后中枢性疼痛调节机制的研究进展 [J]. 中国卒中杂志, 2024, 19(8): 967-972. |
[2] | 汪敏杰, 韩聪, 段炼. 烟雾血管病与免疫相关疾病 [J]. 中国卒中杂志, 2024, 19(7): 747-754. |
[3] | 贾娇坤, 刘改芬, 刘艳芳, 赵性泉, 陈静. 甘油三酯对高血压患者认知功能的影响:一项社区人群的长期队列研究 [J]. 中国卒中杂志, 2024, 19(7): 785-789. |
[4] | 石庆丽, 李越秀, 陈红燕, 王金芳, 王大立, 张玉梅. 缺血性脑白质病变伴认知障碍患者脑网络改变与注意功能的相关性研究 [J]. 中国卒中杂志, 2024, 19(7): 790-796. |
[5] | 王伊龙. 脑小血管病的诊治现状及未来探索之路[J]. 中国卒中杂志, 2024, 19(4): 363-374. |
[6] | 陈玮琪, 徐佳洁, 陆瑶, 王玲, 曹瑾怡, 陈鸿宾, 郭蕾, 吕琰琛, 汤晗, 王赞, 徐非凡, 颜庭梦, 应云清, 仲伟逸, 周蓉, 陆正齐, 程忻, 王伊龙, 中国卒中学会脑小血管病分会. 中国脑小血管病的神经影像学诊断标准及名词标准化定义——来自中国卒中学会的专家共识[J]. 中国卒中杂志, 2024, 19(4): 376-404. |
[7] | 胡琨, 管玲, 王伊龙. 不同神经心理症状与脑小血管病影像学关系的研究进展[J]. 中国卒中杂志, 2024, 19(4): 405-413. |
[8] | 杨营营, 王伊龙. 2013—2023年血管周围间隙相关研究的文献计量学分析[J]. 中国卒中杂志, 2024, 19(4): 414-422. |
[9] | 刘昱君, 刘雷媛, 徐炳东, 韩建邦, 杨冰, 丁燕, 杨英, 孟珩, 张玉生. 伴皮质下梗死和白质脑病的常染色体显性遗传性脑动脉病患者大脑中动脉闭塞血管内治疗1例并文献复习[J]. 中国卒中杂志, 2024, 19(4): 452-458. |
[10] | 潘希娟, 邢英琦, 刘玉梅. 血管超声在脑小血管病中的应用进展[J]. 中国卒中杂志, 2024, 19(3): 343-348. |
[11] | 梁小雪, 郭黎. 肥胖相关慢性炎症与代谢性脑血管病[J]. 中国卒中杂志, 2024, 19(2): 138-144. |
[12] | 傅春玲, 宋碧英, 杨大会. 老年缺血性卒中后轻度认知障碍患者眼-视功能障碍与认知功能的关系研究[J]. 中国卒中杂志, 2024, 19(2): 167-172. |
[13] | 罗冬, 李国梁, 温慧军, 王军文. 系统性免疫炎症指数对急性缺血性卒中后抑郁的预测价值[J]. 中国卒中杂志, 2024, 19(2): 190-196. |
[14] | 代杰, 张素响, 赵沙沙, 张晓凤. 脑小血管病患者认知障碍影响因素分析及列线图模型的构建与验证[J]. 中国卒中杂志, 2024, 19(10): 1136-1142. |
[15] | 鞠佳俊, 王心心, 杭黎华. 脑出血后神经炎症与脑铁代谢的相关性研究进展[J]. 中国卒中杂志, 2024, 19(10): 1205-1214. |
阅读次数 | ||||||
全文 |
|
|||||
摘要 |
|
|||||